Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2014-11-08FDA Approved: GABAPENTIN — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved Amneal Pharmaceuticals LLC's supplemental application for gabapentin (generic anticonvulsant) under the approved ANDA.
-
FDA approval · 2014-11-08FDA Approved: GABAPENTIN — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for gabapentin submitted by Ascend Laboratories, LLC (ANDA 090858).
-
FDA approval · 2014-11-04FDA Approved: LEVETIRACETAM — Supplemental Application (Torrent Pharmaceuticals Limited)
The FDA approved a supplemental application for levetiracetam submitted by Torrent Pharmaceuticals Limited. This action extends the regulato…
-
FDA approval · 2014-11-03FDA Approved: LEVETIRACETAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for levetiracetam from Aurobindo Pharma Limited, updating the regulatory status for this generic pro…
-
FDA approval · 2014-10-23FDA Approved: GABAPENTIN — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approved a supplemental application for gabapentin filed by Quallent Pharmaceuticals Health LLC under ANDA200651, enabling marketing of …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2014-09-26FDA Approved: LAMOTRIGINE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for lamotrigine from Zydus Pharmaceuticals USA Inc., resulting in updated labeling for the gener…
-
FDA approval · 2014-09-26FDA Approved: LEVETIRACETAM — Supplemental Application (BluePoint Laboratories)
FDA approved BluePoint Laboratories' supplemental application for levetiracetam (ANDA 078993), approving a generic version of the anti-seizu…
-
FDA approval · 2014-09-26FDA Approved: LEVETIRACETAM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved a supplemental application for a generic levetiracetam product from Lupin Pharmaceuticals, Inc. (ANDA 078154).
-
FDA approval · 2014-09-24FDA Approved: LEVETIRACETAM — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for levetiracetam from Mylan Pharmaceuticals Inc., granting a supplemental approval under the ANDA f…
-
FDA approval · 2014-09-19FDA Approved: DIVALPROEX SODIUM — Supplemental Application (BluePoint Laboratories)
FDA approves a supplemental application for Divalproex Sodium by BluePoint Laboratories, indicating clearance of a supplemental filing for a…
-
FDA approval · 2014-09-18FDA Approved: LEVETIRACETAM — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for Torrent Pharmaceuticals Limited for levetiracetam. This marks an approval of a supplemental fili…
-
FDA approval · 2014-09-16FDA Approved: TEGRETOL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Tegretol (carbamazepine) submitted by Novartis Pharmaceuticals Corporation. The action updat…
-
FDA approval · 2014-09-16FDA Approved: TEGRETOL XR — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Tegretol XR (carbamazepine) from Novartis Pharmaceuticals Corporation, resulting in updated labe…
-
FDA approval · 2014-08-29FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc., indicating an approval of a supplement to the drug’s…
-
FDA approval · 2014-08-29FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) from UCB, Inc., resulting in a label update.
-
FDA approval · 2014-08-18FDA Approved: NEURONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
FDA approved a supplemental application for Neurontin (gabapentin) by Parke-Davis (Pfizer), resulting in updated labeling.
-
FDA approval · 2014-08-12FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) by UCB, Inc., authorizing changes to the labeling and/or addition of indicat…
-
FDA approval · 2014-08-12FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc. The action updates the product labeling with the new …
-
FDA approval · 2014-08-07FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for KEPPRA (levetiracetam) submitted by UCB, Inc. The approval pertains to the changes described in …
-
FDA approval · 2014-08-07FDA Approved: KEPPRA XR — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for KEPPRA XR (levetiracetam) from UCB, Inc., expanding its approved use/label for this extended…
-
FDA approval · 2014-08-07FDA Approved: KEPPRA — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for Keppra (levetiracetam) submitted by UCB, Inc.
-
FDA approval · 2014-08-05FDA Approved: VALPROIC ACID — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved a supplemental application for Valproic acid submitted by Upsher-Smith Laboratories, LLC.
-
FDA approval · 2014-08-01FDA Approved: KEPPRA XR — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application to add Keppra XR, an extended-release formulation of levetiracetam, to the Keppra product line.
-
FDA approval · 2014-07-03FDA Approved: DILANTIN — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Dilantin (extended phenytoin sodium) by Viatris Specialty LLC. The approval concerns the extende…
-
FDA approval · 2014-07-03FDA Approved: TRILEPTAL — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for TRILEPTAL (oxcarbazepine) from Novartis Pharmaceuticals Corporation.